Live Breaking News & Updates on Novartis Us

Stay updated with breaking news from Novartis us. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Innovation And Healthcare Meet At Novartis

Novartis US executive Andrea Marazzi shares his view on innovation, healthcare challenges, and leadership amid the evolving landscape of medicine. ....

United States , Stephanie Ricci , Andrea Marazzi , North America , Country President , Novartis Canada , Commercial Strategy , Innovation In Healthcare , Novartis Us ,

Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH

First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal. ....

United States , Marrow Transplant Research , International Blood , International Prognostic Scoring Systems , Presentation Details , Novartis Us ,

Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors

Tafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic. ....

United States , Isabella Zinck , Vivek Subbiah , Prnewswire Novartis , Samir Shah , Parag Mahanti , Sloan Simpson , Alina Levchuk , Reshema Kemps Polanco , Division Of Cancer Medicine , University Of Texas Md Anderson Cancer Center , Drug Administration , Exchange Commission , Approval Program , Rare Oncology Agnostic Research , Novartis Pharmaceuticals Corp , Clinical Center , Accelerated Approval Program , Investigational Cancer Therapeutics , Targeted Therapy , Cancer Medicine , Cancer Center , Novartis Oncology , Important Safety , Prescribing Information , East Hanover ,

Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors

Tafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic. ....

United States , Isabella Zinck , Vivek Subbiah , Prnewswire Novartis , Samir Shah , Parag Mahanti , Sloan Simpson , Alina Levchuk , Reshema Kemps Polanco , Division Of Cancer Medicine , University Of Texas Md Anderson Cancer Center , Drug Administration , Exchange Commission , Approval Program , Rare Oncology Agnostic Research , Novartis Pharmaceuticals Corp , Clinical Center , Accelerated Approval Program , Investigational Cancer Therapeutics , Targeted Therapy , Cancer Medicine , Cancer Center , Novartis Oncology , Important Safety , Prescribing Information , East Hanover ,

Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial

Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif® (bosutinib) at 96. ....

United States , East Hanover , Jeff Legos , Jorgee Cortes , Sloan Simpson , Prnewswire Novartis , American Society Of Clinical Oncology , European Hematology Association , Exchange Commission , Global Head Of Oncology Hematology Development , Approval Program , Augusta University , Nj Novartis Pharmaceuticals Corporation , Georgia Cancer Center , Novartis Pharmaceuticals Corp , Clinical Oncology , Executive Vice President , Global Head , Hematology Development , Novartis Commitment , Prescribing Information , Pharmaceuticals Corporation , Randomized Study , Novartis Pharmaceuticals , Allosteric Inhibitor , Tyrosine Kinase Activity ,